---
layout: default
title: Nimodipine
parent: Model Prediction Only (L5)
nav_order: 549
evidence_level: L5
indication_count: 2
---

# Nimodipine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nimodipine: From Cerebral Vasospasm Prevention to Homozygous Familial Hypercholesterolemia

## One-Sentence Summary

Nimodipine is a lipophilic, cerebroselective dihydropyridine calcium channel blocker classically used to prevent cerebral vasospasm following subarachnoid hemorrhage. TxGNN predicts a possible link to **Homozygous Familial Hypercholesterolemia (HoFH)**, but this is currently a **pure model prediction (L5)** — there are **zero clinical trials** and **zero publications** supporting it, and the evidence pack's own mechanistic review flags the connection as pharmacologically implausible.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Cerebral vasospasm prevention after subarachnoid hemorrhage (referenced in evidence pack's mechanistic notes; no formal Canada license record available) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia (HoFH) |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Nimodipine is a dihydropyridine-class, L-type calcium channel blocker whose clinical use is centered on relaxing cerebral vascular smooth muscle to prevent vasospasm after subarachnoid hemorrhage. Its pharmacology is well characterized in this narrow context, but detailed mechanism-of-action data linking it to lipid metabolism is not available in this evidence pack.

HoFH is a distinct disease driven by biallelic mutations in LDLR (or APOB/PCSK9), causing loss of LDL receptor function and markedly elevated LDL-C. Its pathology centers on impaired hepatic clearance of LDL particles — a pathway with no established pharmacological overlap with calcium channel blockade or cerebrovascular smooth muscle tone regulation.

The evidence pack's own mechanistic review is explicit on this point: no literature was found showing a class effect of calcium channel blockers on LDLR expression or LDL metabolism, and the TxGNN link is assessed as likely arising from indirect graph structure (shared metabolic enzyme nodes or drug-drug similarity) rather than a genuine pharmacological relationship. This prediction should therefore be treated as a hypothesis-generating signal only, not a mechanistically grounded candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Nimodipine is not currently marketed in Canada under this evidence pack (market status: Not Marketed; 0 DINs on record), so no product/DIN table is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA/Health Canada label warnings and contraindications are flagged as a blocking data gap in this evidence pack and have not yet been retrieved.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HoFH prediction rests solely on a TxGNN model score (L5) with no supporting clinical trials, literature, or plausible mechanistic pathway — the evidence pack's own review characterizes the link as a likely statistical artifact rather than a real pharmacological relationship. Combined with the absence of Canada market authorization and unresolved safety-label data gaps, this candidate does not meet the bar to proceed.

**To proceed, the following is needed:**
- TFDA/Health Canada package insert data (warnings, contraindications) — currently a blocking gap (DG001)
- Verified mechanism-of-action data for nimodipine beyond cerebrovascular indications (DG002)
- Preclinical or in vitro evidence connecting L-type calcium channel blockade to LDL receptor function or lipid metabolism, before any clinical exploration is considered
- Ongoing monitoring for new literature/trials, given zero current evidence base

*A second candidate (nephrogenic syndrome of inappropriate antidiuresis, TxGNN score 99.05%, also L5/Hold) was flagged in the same evidence pack with similarly weak mechanistic support and no trial/literature evidence — not detailed here but subject to the same Hold status.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

